Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

High level in vivo mucin-type glycosylation in Escherichia coli.

Mueller P, Gauttam R, Raab N, Handrick R, Wahl C, Leptihn S, Zorn M, Kussmaul M, Scheffold M, Eikmanns B, Elling L, Gaisser S.

Microb Cell Fact. 2018 Oct 26;17(1):168. doi: 10.1186/s12934-018-1013-9.

2.

Expression of the functional recombinant human glycosyltransferase GalNAcT2 in Escherichia coli.

Lauber J, Handrick R, Leptihn S, Dürre P, Gaisser S.

Microb Cell Fact. 2015 Jan 13;14:3. doi: 10.1186/s12934-014-0186-0.

3.

Recombinant strains for the enhanced production of bioengineered rapalogs.

Kendrew SG, Petkovic H, Gaisser S, Ready SJ, Gregory MA, Coates NJ, Nur-E-Alam M, Warneck T, Suthar D, Foster TA, McDonald L, Schlingman G, Koehn FE, Skotnicki JS, Carter GT, Moss SJ, Zhang MQ, Martin CJ, Sheridan RM, Wilkinson B.

Metab Eng. 2013 Jan;15:167-73. doi: 10.1016/j.ymben.2012.11.001. Epub 2012 Nov 17.

PMID:
23164580
4.

Synthetic biology in the view of European public funding organisations.

Pei L, Gaisser S, Schmidt M.

Public Underst Sci. 2012 Feb;21(2):149-62.

5.

[The role of biotechnology in pharmaceutical drug design].

Gaisser S, Nusser M.

Z Evid Fortbild Qual Gesundhwes. 2010;104(10):732-7. doi: 10.1016/j.zefq.2010.05.001. Epub 2010 May 27. German.

PMID:
21147436
6.

Shaping the science-industry-policy interface in synthetic biology.

Gaisser S, Reiss T.

Syst Synth Biol. 2009 Dec;3(1-4):109-14. doi: 10.1007/s11693-009-9027-6. Epub 2009 Oct 10.

7.

Making the most of synthetic biology. Strategies for synthetic biology development in Europe.

Gaisser S, Reiss T, Lunkes A, Müller KM, Bernauer H.

EMBO Rep. 2009 Aug;10 Suppl 1:S5-8. doi: 10.1038/embor.2009.118. No abstract available.

8.

Glycosylation engineering of spinosyn analogues containing an L-olivose moiety.

Gaisser S, Carletti I, Schell U, Graupner PR, Sparks TC, Martin CJ, Wilkinson B.

Org Biomol Chem. 2009 Apr 21;7(8):1705-8. doi: 10.1039/b900233b. Epub 2009 Mar 12.

PMID:
19343260
9.

The phantom menace of gene patents.

Gaisser S, Hopkins MM, Liddell K, Zika E, Ibarreta D.

Nature. 2009 Mar 26;458(7237):407-8. doi: 10.1038/458407a. No abstract available.

PMID:
19325609
10.

Pharmacogenetics in Europe: barriers and opportunities.

Gurwitz D, Zika E, Hopkins MM, Gaisser S, Ibarreta D.

Public Health Genomics. 2009;12(3):134-41. doi: 10.1159/000189625. Epub 2009 Feb 10.

11.

EU policies in personalized medicine-related technologies.

Gaisser S, Vignola-Gagné E, Hüsing B, Enzing C, van der Valk T.

Per Med. 2009 Jan;6(1):93-102. doi: 10.2217/17410541.6.1.93.

PMID:
29783384
12.

Engineered biosynthesis of hybrid macrolide polyketides containing D-angolosamine and D-mycaminose moieties.

Schell U, Haydock SF, Kaja AL, Carletti I, Lill RE, Read E, Sheehan LS, Low L, Fernandez MJ, Grolle F, McArthur HA, Sheridan RM, Leadlay PF, Wilkinson B, Gaisser S.

Org Biomol Chem. 2008 Sep 21;6(18):3315-27. doi: 10.1039/b807914e. Epub 2008 Jul 28.

PMID:
18802638
13.

Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors.

Zhang MQ, Gaisser S, Nur-E-Alam M, Sheehan LS, Vousden WA, Gaitatzis N, Peck G, Coates NJ, Moss SJ, Radzom M, Foster TA, Sheridan RM, Gregory MA, Roe SM, Prodromou C, Pearl L, Boyd SM, Wilkinson B, Martin CJ.

J Med Chem. 2008 Sep 25;51(18):5494-7. doi: 10.1021/jm8006068.

PMID:
18800759
14.

Molecular characterization of macbecin as an Hsp90 inhibitor.

Martin CJ, Gaisser S, Challis IR, Carletti I, Wilkinson B, Gregory M, Prodromou C, Roe SM, Pearl LH, Boyd SM, Zhang MQ.

J Med Chem. 2008 May 8;51(9):2853-7. doi: 10.1021/jm701558c. Epub 2008 Mar 22.

PMID:
18357975
15.

Rapamycin biosynthesis: Elucidation of gene product function.

Gregory MA, Hong H, Lill RE, Gaisser S, Petkovic H, Low L, Sheehan LS, Carletti I, Ready SJ, Ward MJ, Kaja AL, Weston AJ, Challis IR, Leadlay PF, Martin CJ, Wilkinson B, Sheridan RM.

Org Biomol Chem. 2006 Oct 7;4(19):3565-8. Epub 2006 Aug 22.

PMID:
16990929
16.

Putting pharmacogenetics into practice.

Hopkins MM, Ibarreta D, Gaisser S, Enzing CM, Ryan J, Martin PA, Lewis G, Detmar S, van den Akker-van Marle ME, Hedgecoe AM, Nightingale P, Dreiling M, Hartig KJ, Vullings W, Forde T.

Nat Biotechnol. 2006 Apr;24(4):403-10.

PMID:
16601719
17.

Mutasynthesis of rapamycin analogues through the manipulation of a gene governing starter unit biosynthesis.

Gregory MA, Petkovic H, Lill RE, Moss SJ, Wilkinson B, Gaisser S, Leadlay PF, Sheridan RM.

Angew Chem Int Ed Engl. 2005 Jul 25;44(30):4757-60. No abstract available.

PMID:
15977283
18.

Isolation and characterization of pre-rapamycin, the first macrocyclic intermediate in the biosynthesis of the immunosuppressant rapamycin by S. hygroscopicus.

Gregory MA, Gaisser S, Lill RE, Hong H, Sheridan RM, Wilkinson B, Petkovic H, Weston AJ, Carletti I, Lee HL, Staunton J, Leadlay PF.

Angew Chem Int Ed Engl. 2004 May 3;43(19):2551-3. No abstract available.

PMID:
15127450
19.

Direct production of ivermectin-like drugs after domain exchange in the avermectin polyketide synthase of Streptomyces avermitilis ATCC31272.

Gaisser S, Kellenberger L, Kaja AL, Weston AJ, Lill RE, Wirtz G, Kendrew SG, Low L, Sheridan RM, Wilkinson B, Galloway IS, Stutzman-Engwall K, McArthur HA, Staunton J, Leadlay PF.

Org Biomol Chem. 2003 Aug 21;1(16):2840-7.

PMID:
12968333
20.

Engineered biosynthesis of novel spinosyns bearing altered deoxyhexose substituents.

Gaisser S, Martin CJ, Wilkinson B, Sheridan RM, Lill RE, Weston AJ, Ready SJ, Waldron C, Crouse GD, Leadlay PF, Staunton J.

Chem Commun (Camb). 2002 Mar 21;(6):618-9.

PMID:
12120151
21.

Parallel pathways for oxidation of 14-membered polyketide macrolactones in Saccharopolyspora erythraea.

Gaisser S, Lill R, Staunton J, Méndez C, Salas J, Leadlay PF.

Mol Microbiol. 2002 May;44(3):771-81.

22.

Analysis of a C-methyltransferase gene (aviG1) involved in avilamycin biosynthesis in Streptomyces viridochromogenes Tü57 and complementation of a Saccharopolyspora erythraea eryBIII mutant by aviG1.

Weitnauer G, Gaisser S, Kellenberger L, Leadlay PF, Bechthold A.

Microbiology. 2002 Feb;148(Pt 2):373-379. doi: 10.1099/00221287-148-2-373.

PMID:
11832501
23.

New erythromycin derivatives from Saccharopolyspora erythraea using sugar O-methyltransferases from the spinosyn biosynthetic gene cluster.

Gaisser S, Lill R, Wirtz G, Grolle F, Staunton J, Leadlay PF.

Mol Microbiol. 2001 Sep;41(5):1223-31.

24.

An ATP-binding cassette transporter and two rRNA methyltransferases are involved in resistance to avilamycin in the producer organism Streptomyces viridochromogenes Tü57.

Weitnauer G, Gaisser S, Trefzer A, Stockert S, Westrich L, Quiros LM, Mendez C, Salas JA, Bechthold A.

Antimicrob Agents Chemother. 2001 Mar;45(3):690-5.

25.

A defined system for hybrid macrolide biosynthesis in Saccharopolyspora erythraea.

Gaisser S, Reather J, Wirtz G, Kellenberger L, Staunton J, Leadlay PF.

Mol Microbiol. 2000 Apr;36(2):391-401.

26.

Novel octaketide macrolides related to 6-deoxyerythronolide B provide evidence for iterative operation of the erythromycin polyketide synthase.

Wilkinson B, Foster G, Rudd BA, Taylor NL, Blackaby AP, Sidebottom PJ, Cooper DJ, Dawson MJ, Buss AD, Gaisser S, Böhm IU, Rowe CJ, Cortés J, Leadlay PF, Staunton J.

Chem Biol. 2000 Feb;7(2):111-7.

27.

Construction of new vectors for high-level expression in actinomycetes.

Rowe CJ, Cortés J, Gaisser S, Staunton J, Leadlay PF.

Gene. 1998 Aug 17;216(1):215-23.

PMID:
9714812
28.

Analysis of eryBI, eryBIII and eryBVII from the erythromycin biosynthetic gene cluster in Saccharopolyspora erythraea.

Gaisser S, Böhm GA, Doumith M, Raynal MC, Dhillon N, Cortés J, Leadlay PF.

Mol Gen Genet. 1998 Apr;258(1-2):78-88.

PMID:
9613575
29.

Sugaring the pill by design.

Gaisser S, Leadlay PF.

Nat Biotechnol. 1998 Jan;16(1):19-20. No abstract available.

PMID:
9447583
30.

Analysis of seven genes from the eryAI-eryK region of the erythromycin biosynthetic gene cluster in Saccharopolyspora erythraea.

Gaisser S, Böhm GA, Cortés J, Leadlay PF.

Mol Gen Genet. 1997 Oct;256(3):239-51.

PMID:
9393448
31.

Cloning of an avilamycin biosynthetic gene cluster from Streptomyces viridochromogenes Tü57.

Gaisser S, Trefzer A, Stockert S, Kirschning A, Bechthold A.

J Bacteriol. 1997 Oct;179(20):6271-8.

33.

A general approach for cloning and characterizing dNDP-glucose dehydratase genes from actinomycetes.

Decker H, Gaisser S, Pelzer S, Schneider P, Westrich L, Wohlleben W, Bechthold A.

FEMS Microbiol Lett. 1996 Aug 1;141(2-3):195-201.

PMID:
8768522
35.

Activity domains of the TonB protein.

Traub I, Gaisser S, Braun V.

Mol Microbiol. 1993 Apr;8(2):409-23.

PMID:
8316089
36.

Supplemental Content

Loading ...
Support Center